1. Atripla: - 24 agosto 2012
  2. Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence. 2010;4:115-2
  3. AA.VV. Bioequivalent Formulation for the Fixed-Dose Regimen of Truvada and TMC278 Finalized. AIDS Patient Care and STDs 2010;24: 395-396
  4. Linee Guida Italiane, sull’utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-1 - - 24 agosto 2012
  5. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. March 27, 2012; 1–167 - - 24 agosto 2012
  6. Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378:238–246
  7. Cohen C, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011;378:229–237
  8. Cohen C, Cassetti I, Chetchotisakd P, Lazzarin A, et al. Pooled week 96 efficacy, resistance, and safety results from the double-blind, randomised, Phase III trials comparing rilpivirine (RPV, TMC278) versus efavirenz (EFV) in treatment-naïve, HIV-1-infected adults IAS, Rome, July 2011: TULBPE032
  9. Nelson M, Behrens G, Cohen C et al. Sustained Efficacy with Low and Similar Rates of Virologic Failures inSecond Year Observed with Rilpivirine (RPV) versus Efavirenz (EFV) plus Emtricitabine/Tenofovir DF (FTC/TDF) in Treatment-Naïve, HIV-1 Infected Adults - Pooled 96-Week ECHO and THRIVE Analysis. 13th European AIDS Conference (EACS) October 12-15, 2011 Belgrade, LBPE7.3/7
© Effetti srl